Fair, or not, pharma is going to continue to come under fire because of high drug prices, but what’s missing is the key fact that even if controls were implemented for prescription drug prices our health care costs would still be escalating. Here is a presentation on high drug prices with some sobering statistics.

083115_diabetescost_THUMB_LARGEWall Street investors, from 2012 to the middle of 2015, have poured more than $50 billion in new capital into the pharma industry, according to Leerink, an investment bank that does equity research.  That influx of cash shifted the character of the industry, says John Rother, head of the nonpartisan advocacy group National Coalition on Health Care. Instead of focusing on time-consuming R&D, drug companies began worrying more about delivering short-term gains to shareholders, he explains.